Pharmaceutical companies (injectable/GLP-1 drug makers)
Customer Exposure
Sales and profitability largely depend on customers' continued sale and development of injectable drug products such as GLP-1s.
Relevance 95·Dependency 90·Confidence 95
Source evidence
“Our business depends to a substantial extent on customers' continued sales and development of products that are delivered by injection, such as GLP-1s.”
Biologic, generic and pharmaceutical drug companies
Revenue Exposure
Proprietary Products segment sales are driven primarily by biologic, generic and pharmaceutical drug customers.
Relevance 92·Dependency 85·Confidence 95
Source evidence
“primarily to biologic, generic and pharmaceutical drug customers”
Biologic, generic and pharmaceutical drug companies
Customer Exposure
Proprietary Products are sold primarily to biologic, generic and pharmaceutical customers whose injectable drug production drives demand; top-10 customers were 47.6% of 2025 net sales with one customer at 15.8%.
Relevance 92·Dependency 80·Confidence 95
Source evidence
“offers elastomers & primary containment, drug delivery devices, integrated systems, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers”
Injectable drug containment and delivery systems
Demand Driver
Order and shipment timing and regulatory actions are disclosed as key drivers of net sales for the containment/delivery product portfolio.
Relevance 90·Dependency 80·Confidence 90
Source evidence
“including product, payer and geographic sales mix, operational effectiveness, pricing realization, timing of orders and shipments, regulatory actions, competition”
Elastomers
Supplier Dependency
Elastomers (synthetic and natural) are a primary raw material; single-source supplier reliance for certain critical raw materials creates supply interruption risk.
Relevance 80·Dependency 78·Confidence 90
Source evidence
“we rely on single-source suppliers for certain critical raw materials.”
FDA, EMA and China NMPA regulation
Regulatory Exposure
Product design, development, manufacturing, marketing and labeling are regulated by FDA, EMA and NMPA; regulatory oversight can impact time and cost of product development and continued availability.
Relevance 78·Dependency 70·Confidence 92
Source evidence
“Regulatory authorities, including regulatory review and oversight, can impact on the time and cost associated with the development and continued availability of our products”
Pharmaceutical, diagnostic, and medical device companies
Customer Exposure
Contract-Manufactured Products segment demand comes primarily from pharmaceutical, diagnostic, and medical device customers.
Relevance 78·Dependency 60·Confidence 92
Source evidence
“focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers”
Foreign currency fluctuations
Currency Exposure
Majority of sales generated internationally with local functional currencies; FX volatility affects results, partially mitigated by hedging.
Relevance 75·Dependency 70·Confidence 92
Source evidence
“fluctuations in foreign currency exchange rates affect the results of our operations and the value of our foreign assets and liabilities”
Pharmaceutical, diagnostic and medical device companies
Customer Exposure
Contract-Manufactured Products segment serves pharmaceutical, diagnostic and medical device customers who incorporate West components into their manufacturing lines.
Relevance 75·Dependency 65·Confidence 90
Source evidence
“Our Contract-Manufactured Products customers include many of the world's largest pharmaceutical, diagnostic, and medical device companies.”
Daikyo Seiko, Ltd.
Supplier Dependency
West depends on its 49%-owned affiliate Daikyo via a distributorship agreement that accounts for the majority of affiliate purchases ($122.6M in 2025) of products West re-sells.
Relevance 75·Dependency 60·Confidence 90
Source evidence
“The majority of the purchase transactions listed above relate to a distributorship agreement with Daikyo that allows us to purchase and re-sell Daikyo products.”
US Dollar
Currency Exposure
FX translation materially affects reported sales; subsidiaries with non-USD functional currency contributed $56.4M favorable translation in 2025.
Relevance 72·Dependency 55·Confidence 95
Source evidence
“including a favorable foreign currency translation impact of $56.4 million”
US tariffs and trade restrictions
Regulatory Exposure
US-imposed tariffs and retaliatory foreign restrictions on goods create cost and demand uncertainty; company monitors and reported no material 2025 impact.
Relevance 70·Dependency 40·Confidence 93
Source evidence
“We continue to monitor this dynamic situation to assess the impact of these tariffs on our business and actions we can take to minimize their impact.”
Aluminum
Raw Material Dependency
Aluminum is one of three primary raw materials used in manufacturing; purchased partly in the open commodities market, creating price-fluctuation exposure.
Relevance 65·Dependency 65·Confidence 88
Source evidence
“We use three primary raw materials in the manufacture of our products: elastomers, aluminum and plastic.”
Global economic conditions
Demand Driver
Downturns, inflation and supply chain disruptions could reduce demand via customer destocking and raw material shortages.
Relevance 65·Dependency 60·Confidence 88
Source evidence
“Those conditions could negatively affect demand for our products due to customers decreasing their inventories in the near-term or long-term”
Inflationary and other market factors influence the cost base and gross profit.
Relevance 65·Dependency 50·Confidence 88
Source evidence
“as well as inflationary and other market factors that influence our cost base”
Aptar
Competitive Exposure
Aptar is a named competitor across Proprietary Products lines.
Relevance 65·Dependency 45·Confidence 90
Source evidence
“we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”
Datwyler
Competitive Exposure
Datwyler is a named competitor across Proprietary Products lines; competition based on design/performance, quality, regulatory compliance, scientific expertise and total cost.
Relevance 65·Dependency 45·Confidence 90
Source evidence
“we compete with several companies, such as Datwyler and Aptar, across our Proprietary Products product lines.”
Plastic
Raw Material Dependency
Plastic is one of three primary raw materials; commodity-market purchases expose results to price fluctuations and inflation.
Relevance 60·Dependency 60·Confidence 88
Source evidence
“We purchase certain raw materials in the open commodities market and therefore the results of our operations may be affected by price fluctuations.”
PFAS packaging regulations
Regulatory Exposure
EU and U.S. state restrictions on PFAS in packaging could require alternative materials and affect results.
Relevance 60·Dependency 55·Confidence 88
Source evidence
“Such regulations restricting or banning PFAS could adversely affect our business and results of operations”
EU/UK GDPR and CCPA/CPRA
Regulatory Exposure
Data privacy compliance obligations worldwide with risk of fines, investigations and processing restrictions.
Relevance 60·Dependency 55·Confidence 93
Source evidence
“we must comply with increasingly complex and rigorous, and sometimes conflicting laws, regulatory standards”
Competition
Competitive Exposure
Competition is disclosed as one of the factors affecting reported net sales in any period.
Relevance 60·Dependency 45·Confidence 85
Source evidence
“regulatory actions, competition, and business acquisitions that involve our customers or competitors”
Third-party payer reimbursement
Demand Driver
Reimbursement levels by Medicare, Medicaid, foreign programs and private insurers influence customer demand and prices.
Relevance 55·Dependency 50·Confidence 85
Source evidence
“Reimbursement rates can also affect the market acceptance rate of new technologies and products.”
Climate change / extreme weather
Raw Material Dependency
Extreme weather has impacted and may impact raw material availability, suppliers, customers, manufacturing and transport; new climate regulations could raise costs.
Relevance 55·Dependency 50·Confidence 85
Source evidence
“increase the frequency or severity of extreme weather events, including droughts, hurricanes, wildfires and flooding”
Foreign currency translation adjustments of $149.2M in 2025 (vs -$112.3M in 2024) materially swing comprehensive income, indicating meaningful non-USD exposure.
Relevance 55·Dependency 40·Confidence 85
Source evidence
“Foreign currency translation adjustments, net of tax of $0.0, $3.6, and $1.0
149.2 (112.3)39.4”
Divestiture counterparty for the SmartDose 3.5mL On-Body Delivery System and associated facilities; $8.4M in charges recorded in 2025.
Relevance 55·Dependency 30·Confidence 90
Source evidence
“the Company's agreement to sell its SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie”